Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

AstraZeneca’s Asthma Drug Receives Expanded Indication from FDA



The drug is already approved for use in patients over the age of 12 for the treatment of asthma as well as chronic obstructive pulmonary disease (COPD).

Share this!

January 31, 2017 | by Sarah Hand, M.Sc.

The US Food and Drug Administration (FDA) has approved AstraZeneca’s Symbicort (budesonide/formoterol fumarate dihydrate) for control of asthma in pediatric patients aged six to 12. The drug is already approved for use in patients over the age of 12 for the treatment of asthma as well as chronic obstructive pulmonary disease (COPD).

Clinical trials conducted as part of AstraZeneca’s Childhood Asthma Safety and Efficacy (CHASE) program were used to support the expanded indication for Symbicort. In particular, the CHASE 3 Phase III clinical trial found that the drug was able to improve lung function in pediatric patients, when delivered via a pressurized metered-dose inhaler (pMDI).

These patients enrolled in the clinical trial were previously symptomatic when medicated with low-dose inhaled corticosteroids. AstraZeneca also reported that the safety profile for Symbicort in pediatric patients was similar to that in adults.

“We are pleased to now be able to also offer Symbicort to younger patients in the US, starting at six years of age, helping to control and prevent asthma symptoms,” said Kai Richter, Vice President Respiratory Medical Affairs, AstraZeneca. “Symbicort continues to be a cornerstone of asthma care around the world and it remains a key medicine in our growing respiratory portfolio.”

Symbicort is an inhaled corticosteroid/long-acting beta2-agonist bronchodilator which controls asthma symptoms by reducing inflammation in the lungs and preventing airways from closing. While over 100 countries have approved Symbicort for the regular treatment of asthma, it is not approved for the treatment of acute bronchospasm in the US.

In the US, it is estimated that 6.3 million children 18 years and younger have been diagnosed with asthma. Physical activity can be a common trigger for asthma symptoms, resulting in reduced participation and increased school absences if the condition is left untreated.

Keywords: Asthma, Drug Indication, FDA


Share this with your colleagues!

Researchers Identify Role of ApoE4 Gene as Possible Drug Target in Alzheimer’s Disease

September 21, 2017 - A team of neurology researchers at Washington University School of Medicine in St. Louis have found that in the presence of the ApoE4 protein, another protein known as tau forms tangles in the brain which contributes to neuronal damage characteristic of Alzheimer’s disease.

Featured In: Life Science News

New Guidelines Address CAR-T Immunotherapy Toxicities to Prevent Patient Deaths

September 20, 2017 - Clinicians at The University of Texas MD Anderson Cancer Center have published new guidelines in the journal, Nature Reviews Clinical Oncology, which could help in the management of these toxicities.

Featured In: Biotech News, Drug Safety News

Microneedle Skin Patch Could Treat Common Metabolic Disorders

September 19, 2017 - Researchers at Columbia University Medical Center (CUMC) and the University of North Carolina have developed a microneedle skin patch impregnated with a drug capable of converting white fat into calorie-burning brown fat.

Featured In: Medical Device News


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.